Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC) -- Ignore unavailable to you. Want to Upgrade?

To: Profiteer who wrote (2786)	7/8/1998 9:13:00 AM
From: ColleenB	Read Replies (2) \| Respond to of 5402

Wow!!! Now that would truly be something!!!

To: Profiteer who wrote (2786)	7/9/1998 1:24:00 AM
From: chirodoc	Respond to of 5402

<<<<, This way when it went into the body, instead of poising the whole body, it goes right to the tumor and penetrates the tumor with the Chemo-therapy. This way you would get more and stronger Chemo to the tumor to kill it. It's call Targeting. We haven't had time to finish this theory, but I'm sure it would work. .......there is a company that is in the lead in this therapy called pharamacyclics - PCYC - their product will seek out tumors and highlight them on imaging--so we know that this is possible. ...but their product is not biologically active (increasing oxygenation) like pher-02. .....conclusion: not only is this idea sensible it is likely one of the primary diagnostic methods that will develop over the next few years. curtis